[go: up one dir, main page]

CA2219080A1 - Regulation d'evenements biologiques fondee sur la rapamycine - Google Patents

Regulation d'evenements biologiques fondee sur la rapamycine Download PDF

Info

Publication number
CA2219080A1
CA2219080A1 CA002219080A CA2219080A CA2219080A1 CA 2219080 A1 CA2219080 A1 CA 2219080A1 CA 002219080 A CA002219080 A CA 002219080A CA 2219080 A CA2219080 A CA 2219080A CA 2219080 A1 CA2219080 A1 CA 2219080A1
Authority
CA
Canada
Prior art keywords
domain
rapamycin
cells
fkbp
frb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002219080A
Other languages
English (en)
Inventor
Timothy Clackson
Dennis A. Holt
Michael Z. Gilman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ariad Gene Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2219080A1 publication Critical patent/CA2219080A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA002219080A 1995-06-07 1996-06-07 Regulation d'evenements biologiques fondee sur la rapamycine Abandoned CA2219080A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48194195A 1995-06-07 1995-06-07
US08/481,941 1995-06-07
US59877696A 1996-02-09 1996-02-09
US60/015,502 1996-02-09

Publications (1)

Publication Number Publication Date
CA2219080A1 true CA2219080A1 (fr) 1996-12-27

Family

ID=27047093

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002219080A Abandoned CA2219080A1 (fr) 1995-06-07 1996-06-07 Regulation d'evenements biologiques fondee sur la rapamycine

Country Status (3)

Country Link
KR (1) KR19990022651A (fr)
CA (1) CA2219080A1 (fr)
WO (1) WO1996041865A1 (fr)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510691B1 (fr) 1991-04-26 2004-11-03 Osaka Bioscience Institute ADN codant un antigène de surface cellulaire humaine
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US6306649B1 (en) 1995-06-27 2001-10-23 Ariad Gene Therapeutics, Inc. Heterologous transcription factors
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6153383A (en) 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
EP1045915A2 (fr) * 1998-01-15 2000-10-25 Ariad Gene Therapeutics, Inc. Regulation de phenomenes biologiques au moyen de proteines chimeres multimeres
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
WO1999058700A1 (fr) * 1998-05-11 1999-11-18 Ariad Gene Therapeutics, Inc. Compositions multivirales et utilisations de celles-ci
DE19831420A1 (de) * 1998-07-14 2000-01-20 Hoechst Marion Roussel De Gmbh Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren
JP2002535958A (ja) * 1998-10-19 2002-10-29 アリアド ジーン セラピューティクス インコーポレイテッド 条件集合ドメインに関する材料および方法
US7109317B1 (en) 1998-11-06 2006-09-19 President And Fellows Of Harvard College FK506-based regulation of biological events
WO2000052179A2 (fr) * 1999-03-03 2000-09-08 Genelabs Technologies, Inc. Syteme de sequence activatrice a mediation assuree par compose de liaison a l'adn
US7189506B1 (en) 1999-03-03 2007-03-13 Genelabs Technologies, Inc. DNA binding compound-mediated molecular switch system
AU3770800A (en) 1999-03-26 2000-10-16 Amgen, Inc. Beta secretase genes and polypeptides
CA2369855A1 (fr) * 1999-05-28 2001-01-04 Sangamo Biosciences, Inc. Commutateurs moleculaires
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
ES2219388T3 (es) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6900043B1 (en) 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
AR030554A1 (es) 2000-03-16 2003-08-27 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
JP2004519205A (ja) 2000-06-28 2004-07-02 アムジェン インコーポレイテッド 胸腺間質リンホポイエチンレセプター分子およびその使用
ES2372031T3 (es) 2001-06-22 2012-01-13 F. Hoffmann-La Roche Ag Complejo soluble que contiene una glicoproteína de superficie retroviral y fkpa o slyd.
GB0123025D0 (en) * 2001-09-25 2001-11-14 Eirx Therapeutics Ltd Apoptosis
KR100956195B1 (ko) 2002-02-01 2010-05-06 어리어드 파마슈티칼스, 인코포레이티드 인 함유 화합물 및 이의 용도
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US7833741B2 (en) 2002-08-07 2010-11-16 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
US7897381B2 (en) 2002-08-07 2011-03-01 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
ES2428354T3 (es) 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
DK1644513T3 (da) 2003-06-20 2011-10-17 Discoverx Corp Assay til detektion af proteinbinding
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
WO2005062708A2 (fr) * 2003-12-29 2005-07-14 Ramot At Tel-Aviv University Ltd. Dosage pour la detection de rapamycine et d'analogues de rapamycine
EP1723239B1 (fr) 2004-02-09 2009-12-09 Synamem Corporation Production de proteines captives
US20060258698A1 (en) 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
EP2001466B1 (fr) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Rapamycine a faible dose destine aux traitement des troubles liées à la perméabilité vasculaire
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EA201990619A1 (ru) 2008-10-10 2019-07-31 Амген Инк. Fgf21 мутанты и их применение
CA2755870C (fr) 2009-03-20 2019-04-09 Angioblast Systems, Inc. Production de cellules pluripotentes reprogrammees
SG10201402038WA (en) 2009-05-05 2014-07-30 Amgen Inc FGF21 Mutants And Uses Thereof
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
EP2440667A1 (fr) * 2009-06-11 2012-04-18 Institut Curie Procédés et ensembles de régulation du trafic intracellulaire d'une protéine cible
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011126808A2 (fr) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Système d'ablation de transgène induit pharmacologiquement
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
JP2013523184A (ja) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
FR2968013A1 (fr) * 2010-11-29 2012-06-01 Cis Bio Int Methode de retention conditionnelle d'une proteine d'interet dans le reticulum endoplasmique
EP2699688A1 (fr) * 2011-04-20 2014-02-26 The Trustees Of The University Of Pennsylvania Régimes et compositions pour l'immunisation passive médiée par aav contre des agents pathogènes en suspension dans l'air
KR101963721B1 (ko) 2011-05-18 2019-03-29 디아소린 에스.피.에이. 샘플 처리 장치 상의 밸빙을 위한 시스템 및 방법
EP2709761B1 (fr) 2011-05-18 2019-08-14 DiaSorin S.p.A. Dispositif et methode de dosage volumetrique sur un dispositif de traitement d' échantillon
AU2012255151B2 (en) 2011-05-18 2015-09-03 Diasorin Italia S.P.A. Systems and methods for detecting the presence of a selected volume of material in a sample processing device
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
CA2905229C (fr) 2013-06-11 2023-10-10 Clontech Laboratories, Inc. Microvesicules enrichies en proteines et leurs procedes de fabrication et d'utilisation
CA2966234A1 (fr) * 2014-12-15 2016-06-23 Bellicum Pharmaceuticals, Inc. Procedes pour eliminer de maniere controlee des cellules therapeutiques
US20190054117A1 (en) * 2014-12-19 2019-02-21 Novartis Ag Dimerization switches and uses thereof
GB201503133D0 (en) * 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
EP3307310A2 (fr) 2015-05-13 2018-04-18 The Trustees Of The University Of Pennsylvania Expression médiée par aav d'anticorps anti-grippaux et leurs procédés d'utilisation
WO2016196655A1 (fr) 2015-06-03 2016-12-08 The Regents Of The University Of California Variants de cas9 et procédés d'utilisation associés
EP3368054A4 (fr) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. Expression régulable au moyen d'un virus adéno-associé (vaa)
WO2017087723A1 (fr) 2015-11-19 2017-05-26 The Regents Of The University Of California Récepteurs de cellules immunitaires répressibles sous conditions et leurs procédés d'utilisation
WO2020047527A2 (fr) 2018-09-02 2020-03-05 F1 Bioventures, Llc Procédés et compositions pour modifier génétiquement des lymphocytes dans le sang ou dans des pbmc enrichies
WO2017180936A1 (fr) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative
JP7206214B2 (ja) 2016-12-13 2023-01-17 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
US11827906B2 (en) 2017-02-28 2023-11-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clade f vector and uses therefor
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
AU2018229293A1 (en) 2017-02-28 2019-08-29 Janssen Biotech, Inc. Influenza vaccines based on AAV vectors
KR20250160517A (ko) 2017-03-03 2025-11-13 엑수마 바이오테크, 코포레이션 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
EP3697449A1 (fr) 2017-10-18 2020-08-26 REGENXBIO Inc. Traitement de maladies oculaires et d'un cancer du côlon métastatique avec un piège à vegf avec modification post-traductionnelle humain
WO2019079496A2 (fr) 2017-10-18 2019-04-25 Regenxbio, Inc. Agents thérapeutiques à base d'anticorps entièrement humains à modification post-traductionnelle
CA3091490A1 (fr) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Cellules resistantes a la rapamycine
IL279329B2 (en) 2018-06-15 2025-01-01 Navitor Pharm Inc Rapamycin analogs and their uses
EP3860642A1 (fr) 2018-10-05 2021-08-11 St. Anna Kinderkrebsforschung Groupe de récepteurs d'antigènes chimériques (car)
EP3632461A1 (fr) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung Groupe de récepteurs d'antigène chimérique (cars)
CA3109747A1 (fr) 2018-10-05 2020-04-09 St. Anna Kinderkrebsforschung Groupe de recepteurs antigeniques chimeriques (car)
EP3632460A1 (fr) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung Groupe de récepteurs d'antigènes chimériques (cars)
LT3898637T (lt) * 2018-12-18 2025-03-10 Novartis Ag Rapamicino dariniai
EP4667578A2 (fr) 2019-04-03 2025-12-24 REGENXBIO Inc. Thérapie génique pour pathologies de l'oeil
SG11202111414RA (en) 2019-04-24 2021-11-29 Regenxbio Inc Fully-human post-translationally modified antibody therapeutics
MX2022002366A (es) 2019-08-26 2022-07-19 Regenxbio Inc Tratamiento de la retinopatía diabética con fab anti-vegf completamente humano modificado postraduccionalmente.
KR20220081365A (ko) 2019-10-07 2022-06-15 리젠엑스바이오 인크. 아데노-연관 바이러스 벡터 약제학적 조성물 및 방법
JP2023506410A (ja) 2019-12-05 2023-02-16 アナクリア セラピューティクス， インコーポレイテッド ラパマイシン類似体及びその使用
EP4213890A1 (fr) 2020-09-15 2023-07-26 RegenxBio Inc. Lanadelumab vectorisé et administration de celui-ci
EP4214242A1 (fr) 2020-09-15 2023-07-26 RegenxBio Inc. Anticorps vectorisés pour thérapie antivirale
IL301643A (en) 2020-10-07 2023-05-01 Regenxbio Inc Gene therapy for ocular manifestations of CLN2 disease
AU2021371307A1 (en) 2020-10-28 2023-06-01 Regenxbio, Inc. VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
WO2022094157A1 (fr) 2020-10-28 2022-05-05 Regenxbio Inc. Anticorps vectorisés anti-cgrp et anti-récepteur de cgrp et leur administration
CN116457373A (zh) 2020-10-29 2023-07-18 再生生物股份有限公司 用于眼部适应症的载体化TNF-α拮抗剂
US20230390418A1 (en) 2020-10-29 2023-12-07 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof
MX2023006444A (es) 2020-12-01 2023-08-10 Univ Pennsylvania Composiciones novedosas con motivos dirigidos a tejido específico y composiciones que los contienen.
WO2022187289A1 (fr) 2021-03-01 2022-09-09 Exuma Biotech Corp. Procédés et compositions pour l'administration de particules rétrovirales
AR125406A1 (es) 2021-04-23 2023-07-12 Univ Pennsylvania Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
WO2023056399A1 (fr) 2021-10-02 2023-04-06 The Trustees Of The University Of Pennsylvania Nouvelles capsides de vaa et compositions les contenant
EP4469584A1 (fr) 2022-01-25 2024-12-04 The Trustees of The University of Pennsylvania Capsides d'aav pour une transduction cardiaque améliorée et un ciblage du foie
WO2023168305A1 (fr) 2022-03-01 2023-09-07 Exuma Biotech Corp. Particules virales comprenant de l'hyaluronidase liée à une membrane
US20250249127A1 (en) 2022-04-14 2025-08-07 Regenxbio Inc. Gene therapy for treating an ocular disease
WO2023205610A2 (fr) 2022-04-18 2023-10-26 Regenxbio Inc. Capsides aav hybrides
EP4518973A1 (fr) 2022-05-03 2025-03-12 RegenxBio Inc. Inhibiteurs vectorisés anti-tnf-alpha pour indications oculaires
WO2023215806A2 (fr) 2022-05-03 2023-11-09 Regenxbio Inc. Anticorps anti-complément vectorisés et agents de complément et leur administration
IL319873A (en) 2022-09-30 2025-05-01 Regenxbio Inc Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB
EP4634394A2 (fr) 2022-12-17 2025-10-22 The Trustees of The University of Pennsylvania Vecteurs mutants aav recombinants avec motifs de ciblage spécifiques des muscles cardiaque et squelettique et compositions les contenant
WO2024130070A2 (fr) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Capsides aav recombinantes avec motifs de ciblage spécifiques du muscle cardiaque et squelettique et leurs utilisations
WO2024238859A1 (fr) 2023-05-16 2024-11-21 Regenxbio Inc. Agents inhibiteurs de c5 vectorisés et leur administration
WO2024238867A1 (fr) 2023-05-16 2024-11-21 Regenxbio Inc. Anticorps anti-complément vectorisés et leur administration
WO2025007046A1 (fr) 2023-06-29 2025-01-02 The Trustees Of The University Of Pennsylvania Aav mutant à motifs de ciblage du système nerveux central et compositions les contenant
WO2025102034A1 (fr) 2023-11-10 2025-05-15 The Trustees Of The University Of Pennsylvania Thérapie génique pour le syndrome de barth
WO2025106661A1 (fr) 2023-11-14 2025-05-22 The Trustees Of The University Of Pennsylvania Compositions ayant des motifs de ciblage spécifiques des muscles cardiaques et squelettiques et leurs utilisations
WO2025217230A1 (fr) 2024-04-08 2025-10-16 Regenxbio Inc. Anticorps anti-complément vectorisés et agents de complément et leur administration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3824633B2 (ja) * 1993-02-12 2006-09-20 ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニアー・ユニバーシティ 標的遺伝子の調節的転写および他の生物学的結果
AU696991B2 (en) * 1993-07-16 1998-09-24 Board Of Trustees Of The Leland Stanford Junior University Regulated apoptosis
US6150137A (en) * 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
EP0776335A4 (fr) * 1994-08-18 1999-09-15 Ariad Gene Therapeutics Inc Elimination modulable d'expression genique, de fonction de produit genique, et de cellules hotes obtenues par genie genetique

Also Published As

Publication number Publication date
KR19990022651A (ko) 1999-03-25
WO1996041865A1 (fr) 1996-12-27

Similar Documents

Publication Publication Date Title
CA2219080A1 (fr) Regulation d'evenements biologiques fondee sur la rapamycine
US6506379B1 (en) Intramuscular delivery of recombinant AAV
US6649595B2 (en) Regulation of biological events using novel compounds
AU755784B2 (en) Regulation of biological events using multimeric chimeric proteins
AU766513B2 (en) Novel dimerizing agents, their production and use
US7067526B1 (en) 28-epirapalogs
US7196192B2 (en) 28-epirapalogs
US6183965B1 (en) Synthetic transcriptional modulators and uses thereof
US5834266A (en) Regulated apoptosis
US6984635B1 (en) Dimerizing agents, their production and use
US6306649B1 (en) Heterologous transcription factors
US8084596B2 (en) Regulated apoptosis
EP0776335A1 (fr) Elimination modulable d'expression genique, de fonction de produit genique, et de cellules hotes obtenues par genie genetique
AU714904B2 (en) Rapamcycin-based regulation of biological events
US20030206891A1 (en) Rapamycin-based biological regulation
EP0833894B1 (fr) Regulation d'evenements biologiques fondee sur la rapamycine

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead